John M. Maraganore

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.

Jeffrey I. Weitz, Monika Hudoba, David Massel et al. · Journal of Clinical Investigation · 1990 · 1.1K citations · Full text

Medicine, Cardiology, Pharmacology +16

Treatment with Bivalirudin (Hirulog) as Compared with Heparin during Coronary Angioplasty for Unstable or Postinfarction Angina

John A. Bittl, John Strony, Jeffrey Brinker et al. · New England Journal of Medicine · 1995 · 496 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin

John M. Maraganore, P Bourdon, Jo-Ann Jablonski et al. · Biochemistry · 1990 · 468 citations

Medicine, Medicinal Chemistry, Pharmacology +13

A status report on RNAi therapeutics

Akshay Vaishnaw, Jared Gollob, Christina Gamba‐Vitalo et al. · Silence · 2010 · 294 citations · Full text

Life Sciences, Genetics, Molecular Genetics +15

A new class of phospholipases A2 with lysine in place of aspartate 49. Functional consequences for calcium and substrate binding.

John M. Maraganore, Gene Merutka, W Cho et al. · Journal of Biological Chemistry · 1984 · 262 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17